Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders (NCT07570212) | Clinical Trial Compass
RecruitingNot Applicable
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
China50 participantsStarted 2025-12-22
Plain-language summary
This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders. The main question it aims to answer is:
* Does individualized targeted rTMS alleviate symptoms of parkinsonian disorders?
* Which clinical manifestations of parkinsonian syndromes are responsive to individualized targeted rTMS, and to what degree?
Procedures:
* Preparation (Screening) Participants will undergo clinical assessments, MRI, and EEG before the treatment.
* Treatment (2 Weeks) Participants will receive a 10-day TMS treatment (once daily, Monday-Friday). Each treatment day takes approximately 3-4 hours. Participants need to keep stable medications and rehabilitation routines during this time.
* Follow-up (10 Weeks) Participants will undergo follow-up assessments at the end of treatment and 10 weeks after treatment. Assessments include clinical scales, MRI, and EEG.
Who can participate
Age range30 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.
✓. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.
✓. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.
✓. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.
Exclusion criteria
✕. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic/magnetic fragments.
✕. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.
What they're measuring
1
Change in motor symptoms measured by MDS-UPDRS Part III
Timeframe: Baseline to post-treatment and 10 weeks after treatment
2
Change in mobility measured by the 5-meter Timed Up and Go test
Timeframe: Baseline to post-treatment and 10 weeks after treatment
3
Change in non-motor symptoms measured by the Non-Motor Symptoms Questionnaire
Timeframe: Baseline to post-treatment and 10 weeks after treatment
✕. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).
✕. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.
✕. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.